The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer

Archive ouverte

Voisin, Allison | Plaschka, Maud | Perrin-Niquet, Marlène | Twardowski, Julie | Boutemine, Insaf | Eluard, Baptiste | Lalle, Guilhem | Stéphan, Pierre | Bouherrou, Khaled | Tonon, Laurie | Pommier, Roxane, M | Ferrari, Anthony | Klein, Ulf | Wencker, Mélanie | Baud, Véronique | Cassier, Philippe | Grinberg-Bleyer, Yenkel

Edité par CCSD ; Frontiers -

International audience. CD8+ T cells are critical mediators of pathogen clearance and anti-tumor immunity. Although signaling pathways leading to the activation of NF-κB transcription factors have crucial functions in the regulation of immune responses, the CD8+ T cell-autonomous roles of the different NF-κB subunits, are still unresolved. Here, we investigated the function of the ubiquitously expressed transcription factor RelA in CD8+ T-cell biology using a novel mouse model and gene-edited human cells. We found that CD8+ T cell-specific ablation of RelA markedly altered the transcriptome of ex vivo stimulated cells, but maintained the proliferative capacity of both mouse and human cells. In contrast, in vivo experiments showed that RelA deficiency did not affect the CD8+ T-cell response to acute viral infection or transplanted tumors. Our data suggest that in CD8+ T cells, RelA is dispensable for their protective activity in pathological contexts.

Suggestions

Du même auteur

NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer

Archive ouverte | Lalle, Guilhem | CCSD

International audience. The outcome of cancer and autoimmunity is often dictated by the effector functions of CD4+ conventional T cells (Tconv). Although activation of the NF-κB signaling pathway has long been impli...

A T cell-intrinsic function for NF-κB RelB in experimental autoimmune encephalomyelitis

Archive ouverte | Lalle, Guilhem | CCSD

International audience. Abstract NF-kappaB (NF-κB) is a family of transcription factors with pleiotropic functions in immune responses. The alternative NF-κB pathway that leads to the activation of RelB and NF-κB2, ...

Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial

Archive ouverte | Voisin, Allison | CCSD

International audience. Abstract Purpose: Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers...

Chargement des enrichissements...